• Robust in-house R&D engine to discover next generation precision oncology and immuno-oncology therapies
• Broad and deep portfolio of differentiated precision oncology therapies targeting highly validated oncogenic drivers to address significant unmet medical needs
• Comprehensive portfolio of small molecule immuno-oncology therapies targeting major types of tumor immune cells
• Proven global clinical development capabilities to bring our drug candidates to the global markets
• Visionary founders, season management team, and blue-chip investors